Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune …
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical …
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more …
General Meeting of Shareholders (GM) to be held on October 28, 2026
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 28, 2026 (CLICK TO VIEW AND DOWNLOAD) PROXY FORM (CLICK TO VIEW AND DOWNLOAD) …
[Read more...] about General Meeting of Shareholders (GM) to be held on October 28, 2026
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands …
